CN110325533B - Menin-mll相互作用的抑制剂 - Google Patents

Menin-mll相互作用的抑制剂

Info

Publication number
CN110325533B
CN110325533B CN201780063763.2A CN201780063763A CN110325533B CN 110325533 B CN110325533 B CN 110325533B CN 201780063763 A CN201780063763 A CN 201780063763A CN 110325533 B CN110325533 B CN 110325533B
Authority
CN
China
Prior art keywords
pyrrolo
pyridin
methyl
fluoro
isopropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780063763.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN110325533A (zh
Inventor
S·卡卡蒂安
D·A·克拉雷蒙
C·董
Y·范
L·贾
S·D·洛特斯塔
S·B·辛格
S·文卡特拉曼
苑晶
Y·郑
L·庄
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vitae Pharmaceuticals LLC
Original Assignee
Vitae Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vitae Pharmaceuticals LLC filed Critical Vitae Pharmaceuticals LLC
Priority to CN202410398451.9A priority Critical patent/CN118359610A/zh
Publication of CN110325533A publication Critical patent/CN110325533A/zh
Application granted granted Critical
Publication of CN110325533B publication Critical patent/CN110325533B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201780063763.2A 2016-09-16 2017-09-15 Menin-mll相互作用的抑制剂 Active CN110325533B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410398451.9A CN118359610A (zh) 2016-09-16 2017-09-15 Menin-mll相互作用的抑制剂

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662395618P 2016-09-16 2016-09-16
US62/395,618 2016-09-16
PCT/US2017/051780 WO2018053267A1 (en) 2016-09-16 2017-09-15 Inhibitors of the menin-mll interaction

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410398451.9A Division CN118359610A (zh) 2016-09-16 2017-09-15 Menin-mll相互作用的抑制剂

Publications (2)

Publication Number Publication Date
CN110325533A CN110325533A (zh) 2019-10-11
CN110325533B true CN110325533B (zh) 2025-11-04

Family

ID=59966892

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780063763.2A Active CN110325533B (zh) 2016-09-16 2017-09-15 Menin-mll相互作用的抑制剂
CN202410398451.9A Pending CN118359610A (zh) 2016-09-16 2017-09-15 Menin-mll相互作用的抑制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410398451.9A Pending CN118359610A (zh) 2016-09-16 2017-09-15 Menin-mll相互作用的抑制剂

Country Status (16)

Country Link
US (3) US10899758B2 (enExample)
EP (2) EP3512850B1 (enExample)
JP (3) JP2019529421A (enExample)
KR (1) KR102536029B1 (enExample)
CN (2) CN110325533B (enExample)
AR (1) AR109658A1 (enExample)
AU (1) AU2017326006B2 (enExample)
CA (1) CA3036987A1 (enExample)
DK (1) DK3512850T3 (enExample)
ES (1) ES2948949T3 (enExample)
FI (1) FI3512850T3 (enExample)
IL (2) IL265028B (enExample)
MX (2) MX2019003091A (enExample)
PL (1) PL3512850T3 (enExample)
TW (1) TWI757340B (enExample)
WO (1) WO2018053267A1 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016040330A1 (en) 2014-09-09 2016-03-17 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
HK1246593A1 (zh) 2015-06-04 2018-09-14 Kura Oncology, Inc. 用於抑制menin蛋白与mll蛋白的相互作用的方法及组合物
AR104020A1 (es) 2015-06-04 2017-06-21 Kura Oncology Inc Métodos y composiciones para inhibir la interacción de menina con proteínas mill
AU2017235462B2 (en) 2016-03-16 2021-07-01 Kura Oncology, Inc. Bridged bicyclic inhibitors of menin-MLL and methods of use
RS64261B1 (sr) 2016-03-16 2023-07-31 Kura Oncology Inc Supstituisani derivati tieno[2,3-d]pirimidina kao inhibitori menin-mll i načini upotrebe
SG11201809714TA (en) 2016-05-02 2018-11-29 Univ Michigan Regents Piperidines as menin inhibitors
PT3468966T (pt) 2016-06-10 2020-11-10 Vitae Pharmaceuticals Llc Inibidores da interação menina-mll
LT3512857T (lt) 2016-09-14 2021-04-12 Janssen Pharmaceutica Nv Menin-mll sąveikos spirobicikliniai inhibitoriai
US12084462B2 (en) 2016-09-14 2024-09-10 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
US10611778B2 (en) 2016-09-14 2020-04-07 Janssen Pharmaceutica Nv Fused bicyclic inhibitors of menin-MLL interaction
MX2019003091A (es) * 2016-09-16 2019-07-08 Vitae Pharmaceuticals Inc Inhibidores de la interaccion de menina-mll.
MX391405B (es) 2016-12-15 2025-03-21 Janssen Pharmaceutica Nv Inhibidores de azepano de la interacción menina-mll.
EP3601249A4 (en) 2017-03-24 2020-12-16 Kura Oncology, Inc. METHODS OF TREATMENT OF MALIGNANT HEMOPATHIES AND EWING'S SARCOMA
JP2020515571A (ja) 2017-03-31 2020-05-28 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 共有結合性メニン阻害剤としてのピペリジン
US11542248B2 (en) 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
US11649251B2 (en) 2017-09-20 2023-05-16 Kura Oncology, Inc. Substituted inhibitors of menin-MLL and methods of use
KR20190043437A (ko) 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
WO2019146740A1 (ja) * 2018-01-26 2019-08-01 塩野義製薬株式会社 ドーパミンｄ３受容体拮抗作用を有する環式化合物
US11325921B2 (en) 2018-03-30 2022-05-10 Sumitomo Dainippon Pharma Co., Ltd. Optically active crosslinked cyclic secondary amine derivative
AU2019327006B2 (en) 2018-08-27 2024-02-15 Sumitomo Pharma Co., Ltd. Optically active azabicyclic derivative
HUE069830T2 (hu) * 2018-09-13 2025-04-28 Kissei Pharmaceutical Imidazopiridinon vegyület
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
US20230030720A1 (en) 2018-12-06 2023-02-02 Daiichi Sankyo Company, Limited Cycloalkane-1,3-diamine derivative
KR102779693B1 (ko) * 2019-09-20 2025-03-12 노파르티스 아게 Mll1 억제제 및 항암제
WO2021060453A1 (ja) * 2019-09-27 2021-04-01 大日本住友製薬株式会社 架橋型光学活性２級アミン誘導体
UA129208C2 (uk) 2019-12-19 2025-02-05 Янссен Фармацевтика Нв Заміщені спіропохідні з прямим ланцюгом
EP4085056A1 (en) 2020-01-03 2022-11-09 Berg LLC Polycyclic amides as ube2k modulators for treating cancer
CN111297863B (zh) * 2020-03-30 2021-06-25 四川大学华西医院 menin-MLL抑制剂在制备治疗子宫内膜癌的药物中的应用
TW202200589A (zh) * 2020-05-28 2022-01-01 瑞士商諾華公司 Ｍｌｌ１抑制劑及抗癌劑
UY39569A (es) 2020-12-17 2022-07-29 Astrazeneca Ab N-(2-(4-cianotiazolidin-3-il)-2-oxoetil)- quinolin-4-carboxamidas
BR112023023154A2 (pt) 2021-05-08 2024-01-23 Janssen Pharmaceutica Nv Derivados espiro substituídos
CN117730081A (zh) 2021-05-08 2024-03-19 詹森药业有限公司 取代的螺环衍生物
EP4337203A4 (en) 2021-05-14 2025-04-09 Syndax Pharmaceuticals, Inc. INHIBITORS OF THE MENIN-MLL INTERACTION
WO2022253167A1 (en) 2021-06-01 2022-12-08 Janssen Pharmaceutica Nv SUBSTITUTED PHENYL-1H-PYRROLO [2, 3-c] PYRIDINE DERIVATIVES
EP4347600A1 (en) 2021-06-03 2024-04-10 JANSSEN Pharmaceutica NV Pyridazines or 1,2,4-triazines substituted by spirocyclic amines
CA3220099A1 (en) 2021-06-17 2022-12-22 Wei Cai (r)-n-ethyl-5-fluoro-n-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-methylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide besylate salt for the treatment of diseases such as cance
CN116903609A (zh) * 2021-11-05 2023-10-20 上海优理惠生医药有限公司 一种化合物、包含其的药物组合物及其应用
US20250000799A1 (en) * 2021-11-11 2025-01-02 V-Ensure Pharma Technologies Private Limited Reconstitutable, Single Use Antidiabetic Compositions
WO2023193790A1 (en) * 2022-04-08 2023-10-12 Janssen Pharmaceutica Nv Crystalline forms of an inhibitor of the menin/mll interaction
WO2024110649A1 (en) 2022-11-24 2024-05-30 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors and menin inhibitors for treating cancer
CN120359221A (zh) * 2022-11-30 2025-07-22 詹森药业有限公司 环丁基取代的双环化合物
JP2025540762A (ja) * 2022-11-30 2025-12-16 ヤンセン ファーマシューティカ エヌ．ベー． メニン－ｍｌｌ阻害剤及びｂｃｌ－２阻害剤を含む組み合わせ
EP4626883A1 (en) * 2022-11-30 2025-10-08 JANSSEN Pharmaceutica NV Substituted 1-phenyl-3, 4-dihydropyrido [3, 4-d] pyrimidin-2-one derivatives
CN120322230A (zh) * 2022-11-30 2025-07-15 詹森药业有限公司 包含多发性内分泌癌蛋白-mll抑制剂和至少一种其他治疗剂的组合
AR132185A1 (es) * 2023-03-24 2025-06-04 Acerta Pharma Bv COMPUESTOS DE 1-H-PIRROLO[2,3-c]PIRIDINA
WO2025067111A1 (zh) * 2023-09-27 2025-04-03 苏州必扬医药科技有限公司 一种Menin-MLL相互作用抑制剂及其制备方法和应用
WO2025119184A1 (zh) * 2023-12-04 2025-06-12 首药控股(北京)股份有限公司 取代的多环化合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103180319A (zh) * 2010-03-15 2013-06-26 普罗克斯马根有限公司 氨基脲敏感性胺氧化酶抑制剂
WO2013102059A1 (en) * 2011-12-30 2013-07-04 Pharmacyclics, Inc. Pyrazolo [3, 4-d] pyrimidine and pyrrolo [2, 3-d] pyrimidine compounds as kinase inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ510587A (en) * 1998-09-18 2003-11-28 Abbott Gmbh & Co 4-aminopyrrolopyrimidines as kinase inhibitors
AU2006239632B2 (en) 2005-04-25 2012-03-15 Merck Patent Gmbh Novel AZA- heterocycles serving as kinase inhibitors
WO2010066629A2 (en) * 2008-12-09 2010-06-17 F. Hoffmann-La Roche Ag Novel azaindoles
TWI500617B (zh) * 2010-05-31 2015-09-21 Ono Pharmaceutical Co Purine ketone derivatives
CN103958510B (zh) 2011-10-03 2016-10-19 北卡罗来纳大学教堂山分校 用于治疗癌症的吡咯并嘧啶化合物
EP2878601B1 (en) * 2012-07-27 2018-03-28 Riken Agent for treating or controlling recurrence of acute myelogenous leukemia
BR112015011171A2 (pt) 2012-11-15 2017-07-11 Pharmacyclics Inc compostos de pirrolopirimidina como inibidores da quinase
WO2014199171A1 (en) * 2013-06-12 2014-12-18 Proximagen Limited New therapeutic uses of enzyme inhibitors
EP3057970A1 (en) * 2013-10-18 2016-08-24 Medivation Technologies, Inc. Heterocyclic compounds and methods of use
EP3269367B1 (en) 2015-03-11 2020-10-07 Riken Therapeutic agent for intractable leukemia
MX2019003091A (es) * 2016-09-16 2019-07-08 Vitae Pharmaceuticals Inc Inhibidores de la interaccion de menina-mll.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103180319A (zh) * 2010-03-15 2013-06-26 普罗克斯马根有限公司 氨基脲敏感性胺氧化酶抑制剂
WO2013102059A1 (en) * 2011-12-30 2013-07-04 Pharmacyclics, Inc. Pyrazolo [3, 4-d] pyrimidine and pyrrolo [2, 3-d] pyrimidine compounds as kinase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Synthesis and Antimicrobial Activity of Some New Pyrazole, Fused Pyrazolo[3,4-d]-pyrimidine and Pyrazolo[4,3-e][1,2,4]-triazolo[1,5-c]pyrimidine Derivatives;Abunada,Nada M.等;《Molecules》;20080729;第13卷(第7期);第1504页scheme3 13b *

Also Published As

Publication number Publication date
IL265028B (en) 2022-09-01
IL295972A (en) 2022-10-01
TWI757340B (zh) 2022-03-11
MX2019003091A (es) 2019-07-08
US11739085B2 (en) 2023-08-29
IL265028A (enExample) 2019-04-30
KR20190111008A (ko) 2019-10-01
PL3512850T3 (pl) 2023-10-09
AU2017326006A1 (en) 2019-03-21
JP2022189853A (ja) 2022-12-22
EP3512850A1 (en) 2019-07-24
DK3512850T3 (da) 2023-07-03
EP4230627A2 (en) 2023-08-23
BR112019005030A2 (pt) 2019-06-18
CN110325533A (zh) 2019-10-11
FI3512850T3 (fi) 2023-06-20
US20210179611A1 (en) 2021-06-17
JP2019529421A (ja) 2019-10-17
NZ751049A (en) 2025-05-02
AU2017326006B2 (en) 2021-10-28
EP3512850B1 (en) 2023-04-12
US20190202830A1 (en) 2019-07-04
MX2022013841A (es) 2022-11-30
AR109658A1 (es) 2019-01-09
EP4230627A3 (en) 2023-11-15
US10899758B2 (en) 2021-01-26
KR102536029B1 (ko) 2023-05-23
CA3036987A1 (en) 2018-03-22
RU2019111169A3 (enExample) 2020-12-30
ES2948949T3 (es) 2023-09-22
US20240124447A1 (en) 2024-04-18
CN118359610A (zh) 2024-07-19
JP2025022910A (ja) 2025-02-14
RU2019111169A (ru) 2020-10-20
WO2018053267A1 (en) 2018-03-22
TW201825486A (zh) 2018-07-16

Similar Documents

Publication Publication Date Title
CN110325533B (zh) Menin-mll相互作用的抑制剂
JP7461390B2 (ja) メニン－ｍｌｌ相互作用の阻害剤
CN108779116A (zh) 多发性内分泌瘤蛋白-mll相互作用的抑制剂
RU2829484C2 (ru) Ингибиторы взаимодействия менин-mll
HK40098918A (en) Inhibitors of the menin-mll interaction
HK40012443A (en) Inhibitors of the menin-mll interaction
HK40012443B (en) Inhibitors of the menin-mll interaction
BR112019005030B1 (pt) Compostos, sais, formas cristalinas, composições farmacêuticas e seus usos como inibidores da interação de menin-llm
HK40007344A (en) Inhibitors of the menin-mll interaction
HK40007344B (en) Inhibitors of the menin-mll interaction

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant